Psoriatic Arthritis
Psoriatic arthritis (PsA) is a complex, chronic, systemic autoimmune inflammatory arthritis that belongs to the seronegative spondyloarthropathies. It combines skin disease of the epidermis with chronic, destructive inflammation of the joints and bones. PsA is driven largely by dysregulation of the IL-23/IL-17 immune axis. Under the influence of genetic factors (such as HLA-B27) and mechanical stress where tendons attach to bone, T-helper 17 (Th17) cells and innate lymphoid cells release large amounts of pro-inflammatory cytokines such as TNF-alpha, IL-17 and IL-22. This cytokine cascade not only drives the excessive keratinocyte proliferation that produces psoriatic plaques, but also activates osteoblasts and osteoclasts in the synovium, leading to bone erosion, fibrosis of the joint capsule and irreversible cartilage destruction.
At Haute-Derma, we approach psoriatic arthritis through the skin–joint axis. Psoriasis is far more than a cosmetic skin problem: up to 30% of people with psoriasis go on to develop psoriatic arthritis, and missing the window of opportunity for joint treatment can lead to permanent disability. Our goal is to pick up hidden signs of arthritis as early as your skin consultation, so we can build a plan that controls both the skin disease and the musculoskeletal damage at the same time.
Our Approach to Treating Psoriatic Arthritis
Psoriatic arthritis is a multifaceted disease that can be disabling, so Haute-Derma follows a "dual inflammation control, function preservation" strategy:
- Early screening with validated tools: Every patient with skin psoriasis at Haute-Derma is regularly screened for joint involvement with the PEST questionnaire (Psoriasis Epidemiology Screening Tool), so silent arthritis can be detected before bone damage appears.
- Phenotype-targeted therapy: We identify each patient's dominant disease pattern (peripheral arthritis, axial disease, enthesitis or dactylitis) to choose the most suitable biologic or targeted immunomodulating drug.
- Multidisciplinary, joint-preserving care: Clinical dermatology, rheumatology and rehabilitation work closely together to switch off systemic inflammation, keep the joints moving as fully as possible and prevent permanent joint fusion.
How We Diagnose Psoriatic Arthritis at Haute-Derma
To confirm PsA and distinguish it reliably from rheumatoid arthritis (RA) or gout, Haute-Derma strictly applies the international CASPAR criteria (ClASsification criteria for Psoriatic ARthritis):
Assessing the Full Clinical Picture
- Peripheral arthritis: Painful swelling of small and large joints, symmetric or asymmetric, with a strong preference for the distal interphalangeal (DIP) joints of the fingers and toes. This is a classic difference from rheumatoid arthritis, which mainly affects the proximal interphalangeal and metacarpophalangeal joints.
- Dactylitis: Swelling of an entire finger or toe, producing a "sausage digit", caused by simultaneous inflammation of the joint capsules, tendons and surrounding soft tissue.
- Enthesitis: Painful inflammation where tendons or ligaments attach to bone, most often the Achilles tendon and the plantar fascia, causing severe heel pain with the first steps out of bed in the morning.
- Characteristic skin and nail changes: We check for psoriatic plaques on the scalp, in skin folds and around the navel, and pay particular attention to psoriatic nail dystrophy (fine pitting like a thimble, nail thickening, onycholysis, oil-drop discoloration under the nail), as it strongly predicts arthritis of the finger joints.
Imaging and Immunological Tests
- Immunological blood tests: We test rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP). In PsA these are usually negative (seronegative arthritis), which helps separate it from rheumatoid arthritis right away. The erythrocyte sedimentation rate (ESR) and CRP may be raised, reflecting systemic inflammation.
- X-rays and high-resolution musculoskeletal (MSK) ultrasound: MSK ultrasound: Detects synovial effusion, increased synovial blood flow (with Doppler) and enthesitis early, before anything is visible to the naked eye.
- Plain X-rays: In later stages, X-rays show a pattern unique to PsA: bone erosion combined with new bone formation, producing the "pencil-in-cup" deformity.
Specialized Treatment at Haute-Derma
Our PsA treatment plans have two goals: fully clearing the psoriatic skin lesions and halting joint destruction with modern immunomodulating therapies:
First-Line Medical Therapy (Conventional DMARDs)
- Conventional synthetic DMARDs (csDMARDs): Drugs such as methotrexate, sulfasalazine or leflunomide are started early for peripheral arthritis. Methotrexate is our first choice at Haute-Derma because it improves both the skin psoriasis and the joint inflammation and pain.
- Nonsteroidal anti-inflammatory drugs (NSAIDs): Short courses of selective COX-2 inhibitors (such as celecoxib or etoricoxib) quickly relieve pain and morning stiffness while patients wait for immunomodulating drugs to take effect. We avoid high-dose oral corticosteroids, as tapering them can trigger a flare of generalized pustular psoriasis.
Targeted Biologic Therapy (bDMARDs and tsDMARDs)
For patients who do not respond to conventional DMARDs, or who have axial disease or severe enthesitis, Haute-Derma uses the most advanced targeted therapies:
- TNF-alpha inhibitors (such as adalimumab, infliximab): Block a key mediator of systemic inflammation, rapidly reducing joint swelling and pain and clearing psoriasis.
- IL-17A inhibitors (such as secukinumab, ixekizumab): A major advance that targets the core disease mechanism of both skin psoriasis and psoriatic arthritis. These drugs achieve high rates of complete skin clearance (PASI 100) and markedly protect cartilage from erosion.
- Janus kinase (JAK) inhibitors (such as tofacitinib): A newer generation of oral small-molecule drugs that block intracellular signaling of pro-inflammatory cytokines, offering convenience and strong efficacy for peripheral arthritis.
